AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25111109
Drug: Yoga exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga exercise (60-minute sessions, twice per week for 8 weeks)
Trial: 23176882
Drug: Trivalent seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent seasonal influenza vaccine (TIV) administered using a 2-step approach (0.1 mL followed by full dose if no reaction)
Trial: 23176882
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) followed by full dose of TIV if no reaction
Trial: 23176882
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of TIV
Trial: 23176882
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose of TIV
Trial: 17618805
Drug: Colonoscopy simulator
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colonoscopy simulator training (treatment group)
Trial: 11600822
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose Nevirapine (NVP)
Trial: 8045951
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone (DEX)
Trial: 23294870
Drug: Ivermectin-metronidazole combined
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin-metronidazole combined therapy
Trial: 19380853
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment duration (72 weeks vs 48 weeks)
Trial: 17082468
Drug: 3APS 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3APS 50 mg BID for 3 months
Trial: 17082468
Drug: 3APS 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3APS 100 mg BID for 3 months
Trial: 17082468
Drug: 3APS 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3APS 150 mg BID for 3 months
Trial: 17082468
Drug: 3APS 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3APS 150 mg BID for 17 months (open-label phase)
Trial: 8157579
Drug: Cefminox 1
RxNorm normalized name: cefminox
DrugBank: Cefminox (DB09062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefminox 1 g
Trial: 8157579
Drug: Cefminox 2
RxNorm normalized name: cefminox
DrugBank: Cefminox (DB09062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefminox 2 g
Trial: 8157579
Drug: Cefminox 1
RxNorm normalized name: cefminox
DrugBank: Cefminox (DB09062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefminox 1 g and 2 g
Trial: 2969232
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d of oral thiamine hydrochloride for three months
Trial: 31135821
Drug: Early dialysis
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early dialysis initiation (estimated GFR >10.5 mL/min/1.73 m2)
Trial: 15784985
Drug: Bread containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread containing resistant starch (6 g of resistant starch derived from tapioca per 2 slices)
Trial: 12403196
Drug: Priorix +
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priorix + Varilrix (varicella vaccine)
Trial: 7023672
Drug: Prazosin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin alone (2 mg single dose)
Trial: 7023672
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 mg t.i.d.) for 3 days
Trial: 7023672
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 mg t.i.d.) + Oxprenolol (40 mg t.i.d.) for 3 days
Trial: 29116691
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO₂) at 2.2 bar for 90 minutes once a day, average number per patient: 4.7 sessions
Trial: 24795252
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sodium restriction and hydrochlorothiazide
Trial: 24795252
Drug: Baseline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline treatment (no sodium restriction or hydrochlorothiazide)
Trial: 9828867
Drug: Aromatherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy with essential oils (thyme, rosemary, lavender, and cedarwood) mixed with carrier oils (jojoba and grapeseed) applied daily.
Trial: 9828867
Drug: Carrier oils
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrier oils (jojoba and grapeseed) applied daily (Control group).
Trial: 371644
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil 480 mg/day
Trial: 31884854
Drug: Canakinumab 50
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 50 mg, 150 mg, 300 mg
Trial: 31124588
Drug: Oral immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunoglobulin supplementation (20 g in milk twice daily for 14 days)
Trial: 31124588
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 g of a product with similar nutritional value but without immunoglobulins in milk, twice daily for 14 days)
Trial: 23301502
Drug: Ganciclovir (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (2.5 mg/kg intravenously)
Trial: 23301502
Drug: Valganciclovir (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (1800 mg orally)
Trial: 19339324
Drug: Recovery Workbook
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery Workbook training in addition to usual treatment (N=16)
Trial: 19339324
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (Control group, N=17)
Trial: 9725552
Drug: Terfenadine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine with atorvastatin
Trial: 355024
Drug: Placebo (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscular injections)
Trial: 11369067
Drug: Conventional computed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional computed tomography-based treatment planning (Group A, n=11)
Trial: 30519531
Drug: Therapist-supported internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-supported internet-based cognitive behavioural therapy (ICBT)
Trial: 15610950
Drug: ziprasidone (80-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone (80-120 mg/day)
Trial: 15610950
Drug: haloperidol (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (5-20 mg/day)
Trial: 12378660
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion 3-6 mg kg‐1 h‐1
Trial: 12378660
Drug: Fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl infusion 10-30 micrograms kg‐1 h‐1
Trial: 10210379
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of epirubicin (1 mg/ml, 50 mg/50 ml solution)
Trial: 10210379
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of epirubicin (2 mg/ml, 100 mg/50 ml solution)
Trial: 2702064
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of 6-mercaptopurine (6-MP) in fasting state
Trial: 2702064
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of 6-mercaptopurine (6-MP) with breakfast
Trial: 178197
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of propantheline bromide
Trial: 31774299
Drug: HELP diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HELP diet with 400 mg/kg Res
Trial: 31774299
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet with 400 mg/kg Res
Trial: 24517156
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (denosumab + teriparatide)
Trial: 17618813
Drug: Arteriovenous fistula
RxNorm normalized name: Cassia fistula whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arteriovenous fistula (AVF) at the wrist for chemotherapy administration
Trial: 17618813
Drug: Chemotherapy through
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy through peripheral veins without AVF (historical controls)
Trial: 15755861
Drug: Estrogen supplementation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen supplementation (2 mg 17beta-estradiol/d)
Trial: 31273513
Drug: Rituximab-based immuno-chemotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab-based immuno-chemotherapy
Trial: 25162217
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg EFV in combination with emtricitabine/tenofovir
Trial: 25162217
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg EFV in combination with emtricitabine/tenofovir
Trial: 19033020
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg sodium selenite daily
Trial: 19033020
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg sodium selenite daily
Trial: 17066642
Drug: Rough-surfaced microthreaded
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough-surfaced microthreaded neck implants (Oneplant)
Trial: 17066642
Drug: Rough-surfaced neck
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough-surfaced neck implants (Stage 1)
Trial: 17066642
Drug: Machined neck
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machined neck implants (Ankylos)
Trial: 12895208
Drug: Choline bitartrate
RxNorm normalized name: Choline Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline bitartrate (50 mg/kg/day)
Trial: 10875609
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor therapy
Trial: 9437195
Drug: Alpha-tocopherol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (50 mg daily) and Beta-carotene (20 mg daily)
Trial: 3669070
Drug: Prompt format
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt format (monthly reminders to self-examine)
Trial: 31542368
Drug: Intranasal ITN
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ITN administration
Trial: 31542368
Drug: Extranasal ITN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extranasal ITN administration (control)
Trial: 31542368
Drug: Intranasal ITN
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ITN administration (Study 2)
Trial: 29735394
Drug: Dorzagliatin 75
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin 75 mg once daily
Trial: 29735394
Drug: Dorzagliatin 100
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin 100 mg once daily
Trial: 29735394
Drug: Dorzagliatin 50
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin 50 mg twice daily
Trial: 29735394
Drug: Dorzagliatin 75
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin 75 mg twice daily
Trial: 23422767
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (7 units) administered subcutaneously
Trial: 23422767
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test with insulin administration
Trial: 23422767
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test without insulin administration
Trial: 12139118
Drug: 3-4 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-4 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Trial: 12139118
Drug: 8-10 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-10 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Trial: 12139118
Drug: 16-18 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-18 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Trial: 2502938
Drug: Penicillin VK
RxNorm normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin VK 500 mg four times daily for five days
Trial: 2502938
Drug: Placebo four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo four times daily for five days
Trial: 2502938
Drug: Penicillin VK
RxNorm normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin VK 500 mg (compliance considered)
Trial: 28872381
Drug: Intermittent sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sequential pneumatic compression (ISPC)
Trial: 17846141
Drug: Cephalexin 500
RxNorm normalized name: cephalexin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 500 mg orally four times a day for 7 days after incision and drainage
Trial: 15221421
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch 5% for 1 week
Trial: 15221421
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch for 12 h daily
Trial: 12516939
Drug: Valaciclovir suspension
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valaciclovir suspension 10 mg/kg
Trial: 12516939
Drug: Valaciclovir suspension
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valaciclovir suspension 20 mg/kg
Trial: 12516939
Drug: Valaciclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 500 mg tablets
Trial: 9828736
Drug: Cisapride 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 0.2 mg/kg/dose four times daily (n = 18)
Trial: 7862849
Drug: Ephedrine (37.5-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (37.5-75 mg)
Trial: 2688064
Drug: naproxen, 750
RxNorm normalized name: Naproxen, 750 mg (as sodium) oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen, 750 mg/day for 1 week
Trial: 2688064
Drug: oxindanac, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxindanac, 600 mg/day for 1 week
Trial: 23064293
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg oral ephedrine
Trial: 21641868
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus zoledronic acid (20 mg per day + 4 mg every 6 months)
Trial: 21641868
Drug: Anastrozole plus
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole plus zoledronic acid (1 mg per day + 4 mg every 6 months)
Trial: 21641868
Drug: Tamoxifen alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen alone (20 mg per day)
Trial: 21641868
Drug: Anastrozole alone
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole alone (1 mg per day)
Trial: 21641868
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg every 6 months)
Trial: 19124803
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (fluorouracil-based therapy)
Trial: 16942532
Drug: Flexible-dose vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible-dose vardenafil (5-20 mg)
Trial: 15254851
Drug: Valerian/hop extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian/hop extract (2 tablets)
Trial: 15254851
Drug: Valerian/hop extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian/hop extract (6 tablets)
Trial: 9537864
Drug: Metadoxine (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metadoxine (1500 mg/day)
Trial: 30528472
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg orally once daily for 6 months
Trial: 27363424
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 100 mg/piece
Trial: 25693137
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml 0.5% isobaric bupivacaine (initial dose) adjusted by 0.1 ml based on previous outcomes
Trial: 24167059
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 7.5 mg/kg/day
Trial: 17223806
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (30 microg.kg‐1)
Trial: 17223806
Drug: Warming with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming with forced-air and intravenous midazolam (30 microg.kg‐1)
Trial: 17223806
Drug: Passive insulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive insulation and intravenous midazolam (30 microg.kg‐1)
Trial: 15226332
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant chemotherapy (no AC)
Trial: 11476129
Drug: Clomipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (mean daily dose, 128.4 mg; range, 100‐150 mg)
Trial: 11476129
Drug: Haloperidol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (mean daily dose, 1.3 mg; range, 1‐1.5 mg)
Trial: 8489062
Drug: Sublingual midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sublingual midazolam (0.2 mg/kg)
Trial: 8489062
Drug: Sublingual flavored
RxNorm normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual flavored midazolam
Trial: 8489062
Drug: Sublingual and
RxNorm normalized name: Buprenorphine and Naloxone Sublingual Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual and intranasal midazolam
Trial: 3687999
Drug: Suspension
RxNorm normalized name: Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension
Trial: 3687999
Drug: Tablet and
RxNorm normalized name: TABLET AND CAPSULE, DOSE PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet and Suspension
Trial: 28940805
Drug: Naloxone-on-release pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone-on-release pack containing a single 'rescue' injection of naloxone
Trial: 25270084
Drug: Artificial dermis
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial dermis (Matriderm) applied in combination with a split-thickness autograft
Trial: 22921098
Drug: Intravasation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravasation of distension fluid > 1000 mL
Trial: 18672538
Drug: Standard triple-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple-drug therapy (LPV/r plus zidovudine/lamivudine)
Trial: 12586507
Drug: Colon-targeted tablets
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon-targeted tablets of mebendazole (50 mg)
Trial: 12586507
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release tablets of mebendazole (50 mg)
Trial: 1387246
Drug: Ondansetron 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.04 mg/kg to 0.35 mg/kg
Trial: 1387246
Drug: Ondansetron 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.01 mg/kg to 0.48 mg/kg
Trial: 3863469
Drug: Mianserin 20-60
RxNorm normalized name: mianserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 20-60 mg
Trial: 3863469
Drug: Imipramine 75-150
RxNorm normalized name: imipramine pamoate 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 75-150 mg
Trial: 26666876
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg for 18 months